SEC Form 4 · accession 0000874015-16-000097
IONIS PHARMACEUTICALS INC · IONS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brett P Monia
Officer — SVP, Antisense Drug Discovery
Period of report
Jan 1, 2016
Accepted (ET)
Jan 4, 2016 · 9:24 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000874015
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 1, 2016 | J | 130 | $47.7105 | A | 4,485 | D | |
| Common StockF3 | Jan 4, 2016 | S | 127 | $61.00 | D | 4,358 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F2 | $61.68 | Jan 4, 2016 | A | 38,240 | A | Jan 4, 2017 | Jan 3, 2023 | Common Stock | 38,240 | 38,240 | D |
Explanation of responses
- F1Reporting 130 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2016. These 130 shares may not be sold until July 2, 2016.
- F2Grant of 1/4/2016 to reporting person of stock options under the Ionis Pharmacueticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/4/2017. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 9,560 shares per year. Following this transaction, the option was exercisable as to 0 on 1/4/2016.
- F3The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 7/1/2014.